BREVIBLOC Drug Patent Profile
✉ Email this page to a colleague
When do Brevibloc patents expire, and what generic alternatives are available?
Brevibloc is a drug marketed by Baxter Hlthcare and is included in one NDA.
The generic ingredient in BREVIBLOC is esmolol hydrochloride. There are eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Brevibloc
A generic version of BREVIBLOC was approved as esmolol hydrochloride by HIKMA on August 10th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BREVIBLOC?
- What are the global sales for BREVIBLOC?
- What is Average Wholesale Price for BREVIBLOC?
Summary for BREVIBLOC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 96 |
Clinical Trials: | 16 |
Patent Applications: | 703 |
Drug Prices: | Drug price information for BREVIBLOC |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BREVIBLOC |
What excipients (inactive ingredients) are in BREVIBLOC? | BREVIBLOC excipients list |
DailyMed Link: | BREVIBLOC at DailyMed |
Recent Clinical Trials for BREVIBLOC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Zagazig University | Phase 2 |
Cristália Produtos Químicos Farmacêuticos Ltda. | Phase 4 |
University Hospital Bispebjerg and Frederiksberg | Phase 4 |
Pharmacology for BREVIBLOC
Drug Class | beta-Adrenergic Blocker |
Mechanism of Action | Adrenergic beta-Antagonists |
US Patents and Regulatory Information for BREVIBLOC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baxter Hlthcare | BREVIBLOC | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-003 | Aug 15, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Baxter Hlthcare | BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-005 | Jan 27, 2003 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Baxter Hlthcare | BREVIBLOC | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-006 | Feb 25, 2003 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Baxter Hlthcare | BREVIBLOC | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-007 | May 28, 2003 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Baxter Hlthcare | BREVIBLOC IN PLASTIC CONTAINER | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-004 | Feb 16, 2001 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BREVIBLOC
International Patents for BREVIBLOC
See the table below for patents covering BREVIBLOC around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 0053435 | COMPOUNDS SUITABLE FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS | ⤷ Sign Up |
Egypt | 16108 | METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS | ⤷ Sign Up |
Japan | H0720861 | ⤷ Sign Up | |
Poland | 357387 | ⤷ Sign Up | |
China | 1455669 | ⤷ Sign Up | |
Denmark | 164660 | ⤷ Sign Up | |
Denmark | 335082 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |